SBC Medical Group Holdings Inc. (NASDAQ: SBC) reported a year of substantial growth in 2025, marked by clinic expansion, strategic acquisitions, and entry into new international markets. The Japanese owner and operator of aesthetic medical clinics pursued strategies to make aesthetic medicine more accessible while differentiating itself with advanced treatments and competitive pricing. These initiatives resulted in a 15% year-over-year increase in franchise locations to 258 as of September 30, 2025, and a 5% sequential increase in average revenue per customer visit to $298 during the third quarter.
The company's growth was fueled by multiple factors, including a revised pricing strategy that attracted higher revenue-generating customers and boosted the repeat business rate to 72%. SBC Medical expanded its service offerings to include plastic surgery and infertility treatment, while also launching new brands like "Neo Skin Clinic" and "Hada no Aozora Clinic" in Tokyo. The latter employs a hybrid dermatology model that integrates insurance-covered general dermatology with private-pay aesthetic treatments.
Strategic acquisitions played a crucial role in SBC Medical's expansion. The company acquired MB Career Lounge Co. Ltd., a provider of management support services for medical institutions specializing in consulting, training and human resources solutions. This acquisition, detailed in their corporate communications, enhances SBC Medical's operational capabilities. Additionally, SBC acquired a related subsidiary, Waqoo, to accelerate research and development in clinical areas such as AGA and orthopedics, while jointly developing skincare products.
International expansion formed another key component of SBC Medical's growth strategy. The company entered Singapore and Thailand markets, with plans for U.S. expansion in early 2026. In Singapore, SBC expanded its collaboration with Aesthetic Healthcare Holdings Pte. Ltd., which operates multiple brands in the medical aesthetics industry. In Thailand, SBC signed an e-consulting agreement with BLEZ ASIA Co. Ltd., which operates more than 20 pharmacies and clinics. According to company reports available at https://www.newmediawire.com, this partnership represents a significant step toward entering the growing Thai market.
The company also targeted Chinese consumers visiting Japan for cosmetic procedures, enhancing its appeal through Chinese-speaking staff, social media outreach, and events in Shanghai. This strategy capitalizes on Japan's reputation for advanced techniques and qualified medical staff that attract medical tourists.
Financial developments further strengthened SBC Medical's position. The company was added to the Russell 3000® Index, increasing its visibility among institutional and individual investors who invest in index funds and ETFs tracking Russell indexes. SBC Medical also announced a stock buyback program of up to $5 million, reflecting confidence in its growth potential. The company ended the third quarter with improved net profit as it returned to a more typical cost structure following IPO-related expenses.
These developments position SBC Medical to capitalize on the growing global cosmetic surgery and procedure market, which was valued at $122.08 billion in 2022 and is expected to grow at a compound annual growth rate of 14.7% from 2023 to 2030. The company's expansion comes as the aesthetics and cosmetic medical market in Japan attracts increasing numbers of affluent Chinese and other Asian consumers seeking advanced treatments.
